Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening

Rachel G. Sinkey, Anthony O. Odibo

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Cost-effectiveness analyses allow assessment of whether marginal gains from new technology are worth increased costs. Several studies have examined cost-effectiveness of Down syndrome (DS) screening and found it to be cost-effective. Noninvasive prenatal screening also appears to be cost-effective among high-risk women with respect to DS screening, but not for the general population. Chromosomal microarray (CMA) is a genetic sequencing method superior to but more expensive than karyotype. In light of CMAs greater ability to detect genetic abnormalities, it is cost-effective when used for prenatal diagnosis of an anomalous fetus. This article covers methodology and salient issues of cost-effectiveness.

Original languageEnglish
Pages (from-to)237-248
Number of pages12
JournalClinics in Laboratory Medicine
Issue number2
StatePublished - Jun 1 2016


  • Cost-benefit analysis
  • Cost-effectiveness analysis
  • Down syndrome
  • Economics
  • Noninvasive prenatal screening
  • Prenatal diagnosis-economics


Dive into the research topics of 'Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening'. Together they form a unique fingerprint.

Cite this